Robert Motzer, MD, Elizabeth Plimack, MD, MS, and Brian Rini, MD discuss recent treatment updates for patients with advanced renal cell carcinoma (RCC) and their implications for the RCC treatment landscape and clinical practice.
EP. 1: Overview of Advanced Renal Cell Carcinoma
An overview of advanced Renal Cell Carcinoma (aRCC), including its prevalence, patient presentation, classification, and treatment criteria.
EP. 2: First-Line Combination Options in Advanced Renal Cell Carcinoma
Discussion centered around available first-line combination options for patients with aRCC as well as factors influencing treatment choice.
EP. 3: 4-Year Follow-Up Results of Lenvatinib Plus Pembrolizumab in Frontline aRCC
Panelists analyze the 4-year follow-up results of the CLEAR study, covering study design, efficacy, safety, and clinical implications.
EP. 4: Dosing and Tolerability of First-line Treatment Options in Clinical Practice
The panel engages in a discussion on lenvatinib dosing in clinical practice, addressing dose reductions, their impact on treatment effectiveness, and real-world tolerability.
EP. 5: Insights from the Community: Optimizing Care for Patients with aRCC
Expert oncologists share experiences and insights on key treatment protocols for patients with aRCC, including perspectives from community oncologists.
EP. 6: Novel Doublet Combination Regimens in Frontline Advanced RCC
Panelists provide insight on ongoing studies evaluating doublet combinations in frontline advanced RCC.
EP. 7: Novel Triplet Combination Regimens in Frontline RCC
Ongoing studies assessing triplet regimens in frontline advanced RCC and their influence on treatment decisions are discussed, including efficacy outcomes.
EP. 8: Unmet Needs and Future Outlook in aRCC Treatment
The panel explores unmet needs in aRCC treatment and shares expectations for changes and advances in the landscape in the near future.
2 Clarke Drive Cranbury, NJ 08512